Valuation: Endonovo Therapeutics Inc

Market Cap 2.77M 2.38M 2.22M 2.03M 3.82M 265M 3.87M 26.26M 10.24M 133M 10.41M 10.19M 441M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.5M 7.96M 7.28M 13.67M 950M 13.85M 94M 36.66M 477M 37.27M 36.46M 1.58B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2012
Investor Relations Contact - 01/05/2014
Corporate Officer/Principal 77 30/11/2022
Director TitleAgeSince
Chairman 61 01/03/2012
Change 5-day change 1-year change 3-year change Capi.($)
-3.00%+2.27%+77.60%+109.33% 72.12B
+1.90%+23.53%+56.60%+97.76% 65.85B
+5.12%+25.22%+5.24%-0.82% 29.28B
+0.55%+1.64%-5.15%+471.68% 27.47B
+2.74%+12.98%+62.84%+28.14% 26.7B
+0.47%+6.12%+36.66%-13.79% 20.06B
+1.82%-6.67%+247.46%+393.10% 18.22B
+0.94%+3.36%+18.55%+532.94% 16.4B
+0.73%+5.54%+39.71%+153.07% 13.4B
Average +1.25%+8.36%+59.94%+196.82% 32.17B
Weighted average by Cap. +0.74%+9.48%+59.05%+157.80%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.05 0.1 6.99 0.1 0.69 0.27 3.51 0.27 0.27 11.62 0.14 0.12 0.11 0.1 0.19 12.95 0.19 1.28 0.5 6.51 0.51 0.5 21.52
Net income -3.1M -2.66M -2.49M -2.28M -4.28M -297M -4.33M -29.4M -11.47M -149M -11.66M -11.4M -494M -18.47M -15.83M -14.81M -13.55M -25.44M -1.77B -25.77M -175M -68.22M -888M -69.37M -67.86M -2.94B
Net Debt 7.1M 6.08M 5.69M 5.21M 9.77M 679M 9.9M 67.19M 26.2M 341M 26.64M 26.06M 1.13B 7.15M 6.13M 5.73M 5.25M 9.85M 684M 9.98M 67.74M 26.42M 344M 26.86M 26.27M 1.14B
Logo Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-